Associated tags: Cell, Patient, Pharmaceutical industry, Gesellschaft mit beschränkter Haftung, Cancer, Biotechnology, Vaccine, Medical imaging, CMSO, TILS, Immunotherapy, Safety, Gene expression, Epic, Glioblastoma
Locations: MA, FLORIDA, VIENNA, AT, AUSTRIA, SAN FRANCISCO, ÖSTERREICH
Retrieved on:
Thursday, December 21, 2023
VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January 8-11, 2024.
Key Points:
- VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January 8-11, 2024.
- Members of the invIOs management team will be available for one-on-one meetings to showcase the Company’s dynamic immuno-oncology pipeline and discuss its corporate strategy and plans for 2024.
- Please contact [email protected] to schedule a meeting.
Retrieved on:
Thursday, November 9, 2023
Survival,
Temozolomide,
Harvard Medical School,
Dana–Farber Cancer Institute,
Gesellschaft mit beschränkter Haftung,
Biotechnology,
MD,
Cytokine,
Doctor of Philosophy,
Research,
Traffic barrier,
Science,
Immune system,
Cancer,
Radiation,
European Association of Urology,
Brain,
Neuro-Oncology (journal),
Patient,
Glioblastoma,
Pharmaceutical industry,
Medical imaging,
Medicine Preclinical study will be conducted by Dr. David Reardon’s research group
Key Points:
- Preclinical study will be conducted by Dr. David Reardon’s research group
VIENNA, Austria and BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
- The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
- Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
- After seeing the initial promising preclinical data on INV501 in solid tumors presented by invIOs, we are excited to test this small molecule that crosses the blood-brain barrier in glioblastoma models.
Retrieved on:
Tuesday, September 5, 2023
GMP,
Index,
Progression-free survival,
Neoplasm,
FFG,
Biotechnology,
Clinical trial,
Cancer,
Lung cancer,
Austrian Research Promotion Agency,
Head,
Medical school,
Epic,
Biomarker,
Neck,
PFS,
Gesellschaft mit beschränkter Haftung,
Small RNA,
Science,
Protein,
AGES,
Patient,
Medical University of Innsbruck,
Immune system,
TME,
MMD,
MTD,
ORR,
Safety,
Pharmaceutical industry,
Medical imaging,
Vaccine VIENNA, Austria, Sept. 05, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that it has started patient recruitment for a Phase 1b trial of its novel autologous cell therapy, APN401, in patients with solid tumors, and has successfully secured grant funding.
Key Points:
- VIENNA, Austria, Sept. 05, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that it has started patient recruitment for a Phase 1b trial of its novel autologous cell therapy, APN401, in patients with solid tumors, and has successfully secured grant funding.
- PALINDROM is a multi-center trial taking place in Austria with two GMP-compliant manufacturing sites in Vienna and Linz.
- As part of the Austrian Life Sciences Programme 2023 initiative, the Austrian Research Promotion Agency (FFG) has awarded invIOs funding to support the PALINDROM study.
- “I am delighted that the Austrian government is supporting our latest clinical trial using the EPiC cell therapy platform to develop an innovative and potentially game-changing approach to treating solid tumors,” said Peter Llewellyn-Davies, CEO of invIOs.
Biotechnology,
Survival,
Cancer,
IP,
Gesellschaft mit beschränkter Haftung,
Patient,
Melanoma,
Cytokine,
European Association of Urology,
Breast cancer,
Pharmaceutical industry,
Vaccine INV501 comprises a class of novel small molecules that can selectively enhance tumor-reactive cytotoxicity in preclinical in vivo model systems.
Key Points:
- INV501 comprises a class of novel small molecules that can selectively enhance tumor-reactive cytotoxicity in preclinical in vivo model systems.
- Similarly, in a breast cancer model using EO771 cells, tumor growth was significantly inhibited and survival prolonged even beyond the end of treatment.
- “These promising preclinical data highlight the exciting potential of invIOs’s novel small molecule, INV501, in solid tumor indications where medical need is high.
- INV501 also increases T cell proliferation and strengthens T cell mediated killing of melanoma cells in a dose-dependent manner.
AACR,
Progression-free survival,
Biotechnology,
Clinical trial,
Cancer,
American Association for Cancer Research,
Head,
Medical school,
Medical University of Vienna,
Neck,
Gesellschaft mit beschränkter Haftung,
Patient,
HNSCC,
Poster,
Pharmaceutical industry,
Medical imaging Both patients were part of invIOs’s recently completed Phase 1b trial and achieved stable disease for up to 6 months during treatment with APN401.
Key Points:
- Both patients were part of invIOs’s recently completed Phase 1b trial and achieved stable disease for up to 6 months during treatment with APN401.
- In addition, the study confirmed that invIOs’s cell therapy platform represents a feasible approach for rapid local manufacturing of a Cbl-b silenced cell therapy, enabling out-patient treatment with vein-to-vein times of less than 24 hours.
- Furthermore, analysis of the patients’ T cells before each infusion cycle showed an increase in T cell clonality during the treatment period.
- Larger trials beyond the case series are now needed to derive a definitive conclusion regarding the clinical activity of this novel approach.”
Retrieved on:
Wednesday, December 14, 2022
Conference,
Immunotherapy,
Gesellschaft mit beschränkter Haftung,
Biotechnology,
CMSO,
Epic,
Cancer,
TILS,
Gene expression,
IO,
Glioblastoma,
Patient,
Pharmaceutical industry,
Medical imaging VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.
Key Points:
- VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.
- Peter and CMSO Dr Romana Gugenberger are available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.
- Details of the invIOs presentation at Biotech Showcase are as follows:
invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of innovative cancer immunotherapies.
- Once clinically validated, this novel concept will allow access to and treatment for indications not previously addressable by immunotherapy.
Retrieved on:
Thursday, November 10, 2022
GLOBE,
Thomas Jefferson National Accelerator Facility,
IO,
Immunity,
Escape Room,
Convention center,
Poster,
Medical University of Vienna,
Immunotherapy,
Cancer,
Department,
Gesellschaft mit beschränkter Haftung,
Serology,
MTD,
Glioblastoma,
Boston Convention and Exhibition Center,
TILS,
Alveolar soft part sarcoma,
Safety,
Gene expression,
CMSO,
Sirna,
SITC,
Disease,
Neoplasm,
Clinical trial,
Cell,
Liver,
Biotechnology,
Medical school,
Patient,
Immune system,
Peritoneum,
Index (publishing),
Hematological Cancer Research Investment and Education Act,
Society,
Transfusion medicine,
Vaccine,
Pharmaceutical industry,
Medical imaging,
Epic Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.
Key Points:
- Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.
- Treatment with APN401 was well tolerated and the patient presented with stable disease for 27 weeks, suggesting immunological anti-tumor activity resulting from treatment with APN401.
- This supports the potency of APN401 and its potential as an effective therapeutic for malignancies, which is being further investigated in the ongoing clinical trial.
- APN401 is currently being evaluated in a Phase 1b clinical trial in patients with advanced solid tumors.
Retrieved on:
Thursday, November 3, 2022
Medical University of Vienna,
Blood pressure,
Severe acute respiratory syndrome coronavirus 2,
Heart,
Ageing,
MAD,
SADS,
Death,
Degenerative disease,
Vascular remodelling in the embryo,
GLOBE,
Kidney disease,
Science,
Principal,
Safety,
Adult,
APN01,
Department,
Toxicity,
Ventilation,
COVID-19,
Gene expression,
ACE,
Acute respiratory distress syndrome,
Medical school,
CEO,
Inhalation,
Lung,
Pharmacology,
PAH,
Hypertensive emergency,
Patient safety,
ACE2,
RAAS,
Hydrolysis,
Inflammation,
Liver,
Mads,
Respiratory disease,
Achievement,
Kidney,
Immunotherapy,
Patient,
Gesellschaft mit beschränkter Haftung,
Pharmacokinetics,
Administration,
Vaccine,
Pharmaceutical industry,
Arester Earl In a completed double-blind, placebo-controlled Phase 2 trial, intravenously administered APN01 showed potential clinical benefit against COVID-19.
Key Points:
- In a completed double-blind, placebo-controlled Phase 2 trial, intravenously administered APN01 showed potential clinical benefit against COVID-19.
- With the current trial of inhaled APN01 and our previous Phase 2 trial using intravenous administration in COVID-19, we have shown that APN01 is a safe and well tolerated potential treatment approach for a number of respiratory diseases.
- The double-blind, placebo-controlled, dose-escalation study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled APN01.
- The first EPiC-based candidate, APN401, is currently being evaluated in a clinical Phase 1b trial in patients with advanced solid tumors.
Retrieved on:
Tuesday, October 18, 2022
Gene expression,
Immunotherapy,
SITC,
Poster,
Biotechnology,
IO,
Patient,
JITC,
Convention center,
Boston Convention and Exhibition Center,
CMSO,
Gesellschaft mit beschränkter Haftung,
Society,
Thomas Jefferson National Accelerator Facility,
Abstract (summary),
Epic,
2021 Essex County Council election,
Journal,
GLOBE,
Glioblastoma,
TILS,
Pharmaceutical industry,
Medical imaging,
Cancer The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOss EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.
Key Points:
- The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOss EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.
- Dr. Romana Gugenberger, CMSO, and Dr. Alexander Dohnal, Head of R&D, will attend SITC 2022 and are available for meetings during the event.
- The Poster Hall will be open from 9 a.m. to 9 p.m. on Thursday, November 10, 2022, and from 9 a.m. to 8:30 p.m. on Friday, November 11, 2022.
- The ePosters will also be available to attendees on the SITC 2022s Virtual ePoster Hall, as well as on the SITC meeting app and the SITC virtual meeting platform.
Retrieved on:
Tuesday, October 11, 2022
Gene expression,
List of convention and exhibition centers,
Conference,
Biotechnology,
IO,
LSX,
Patient,
Cancer,
Exhibition,
Cell therapy,
CMSO,
Industry,
Gesellschaft mit beschränkter Haftung,
CEO,
CEST,
Immunotherapy,
GLOBE,
Jefferies,
Glioblastoma,
TILS,
Epic,
Pharmaceutical industry,
Cryptocurrency,
Medical imaging VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (invIOs), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv$tival Showcase and the Jefferies 2022 London Healthcare Conference.
Key Points:
- VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (invIOs), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv$tival Showcase and the Jefferies 2022 London Healthcare Conference.
- A digital company presentation by Peter Llewellyn-Davies is available now online via the event partnering system.
- Peter Llewellyn-Davies will present invIOss cell therapy platform, EPiC, and pipeline of clinical and pre-clinical assets on the Biotech Late Growth Stage.
- invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of innovative cancer immunotherapies.
